DA Davidson analyst Michael Shlisky lowered the firm’s price target on Standex (SXI) to $200 from $207 and keeps a Buy rating on the shares after its Q3 results. The company had one negative organic quarter left, but it looks like this trend is inflecting starting with the current quarter, the analyst tells investors in a research note. Organic growth could accelerate in the second half of FY26 as Amran/Narayan laps its first year in the portfolio, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SXI:
- Standex International’s Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating
- Standex International Reports Strong Q3 2025 Results
- Standex International’s Earnings Call: Record Margins Amid Challenges
- Standex International: Strategic Acquisitions and Operational Resilience Drive Buy Rating
- Standex reports Q3 adjusted EPS $1.95, consensus $1.92